GlaxoSmithKline: Lymphoma, Follicular trials
The registry lists 12 Lymphoma, Follicular studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 1 3Phase 2 3Phase 3 3Phase 4 3No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) PatientsCompletedNCT00494780Phase 2Results posted
- SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In AdultsCompletedNCT00461500Phase 4Results posted
- SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)CompletedNCT00455923Phase 4Results posted
- Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedNCT00428090Phase 3Results posted
- HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to RituximabCompletedNCT00394836Phase 2Results posted
- Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedNCT00348140Phase 3Results posted
- Long-term Study Of Ropinirole In Restless Legs SyndromeCompletedNCT00329602Phase 4Results posted
- A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's LymphomaCompletedNCT00315731Phase 1Results posted
- Patient-Reported Outcome Measurement Information System (PROMIS) Physical FunctionCompletedNCT03351140
- Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00742144Phase 1
- A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic RegimenWithdrawnNCT00319332Phase 3
- Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular LymphomaWithdrawnNCT00092274Phase 1/2